Chemistry:Axitinib
 | |
| Clinical data | |
|---|---|
| Trade names | Inlyta, Axinix |
| Other names | AG013736 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a612017 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 58%[2] |
| Protein binding | >99%[2] |
| Metabolism | Liver (mostly CYP3A4/CYP3A5-mediated but with some contributions from CYP1A2, CYP2C19, UGT1A1)[2] |
| Elimination half-life | 2.5-6.1 hours[2] |
| Excretion | Feces (41%; 12% as unchanged drug), urine (23%)[2] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| PDB ligand | |
| Chemical and physical data | |
| Formula | C22H18N4OS |
| Molar mass | 386.47 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Axitinib, sold under the brand name Inlyta, is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models[3] and has shown partial responses in clinical trials with renal cell carcinoma (RCC)[4] and several other tumour types.[5]
It was approved to treat renal cell carcinoma by the U.S. Food and Drug Administration after showing a modest increase in progression-free survival,[6] though there have been reports of fatal adverse effects.[7]
Approvals and indications
Renal cell carcinoma
It has received approval for use as a treatment for renal cell carcinoma from the US Food and Drug Administration (FDA) (27 January 2012), the European Medicines Agency (EMA) (13 September 2012), the UK Medicines and Healthcare products Regulatory Agency (MHRA) (3 September 2012) and the Australian Therapeutic Goods Administration (TGA) (26 July 2012).[1][8][9][10]
Clinical trials
A Phase II clinical trial showed good response in combination chemotherapy with gemcitabine for advanced pancreatic cancer.[11] However, Pfizer reported on January 30, 2009, that Phase III clinical trials of the drug when used in combination with gemcitabine showed no evidence of improved survival rates over treatments using gemcitabine alone for advanced pancreatic cancer and halted the trial.[12]
In 2010, a Phase III trial for previously treated metastatic renal cell carcinoma (mRCC) showed significantly extended progression-free survival when compared to sorafenib.[13] In December 2011, the Oncologic Drugs Advisory Committee (ODAC) voted unanimously to recommend that US FDA approve axitinib for the second-line treatment of patients with advanced renal cell carcinoma (RCC), based on the results of the Phase III trial comparing axitinib and sorafenib.[14]
It has also been studied in combination with the ALK1 inhibitor dalantercept.[15]
A study published in 2015[16] showed that axitinib effectively inhibits a mutated gene (BCR-ABL1[T315I]) that is common in chronic myeloid leukemias and adult acute lymphoblastic leukemias which have become resistant to other tyrosine kinase inhibitors like imatinib. This is one of the first examples of a new indication for an existing drug being discovered by screening known drugs using a patient's own cells.
Adverse effects
Diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, hand-foot syndrome, weight decreased, vomiting, asthenia, and constipation are the most common side effects occurring in more than 20% of patients.[17]
Interactions
Coadministration with strong CYP3A4/CYP3A5 inhibitors should be avoided where possible as they may reduce plasma clearance of axitinib.[2]
Mechanism of action
Its primary mechanism of action is thought to be vascular endothelial growth factor receptor 1–3, c-KIT and PDGFR inhibition, this, in turn, enables it to inhibit angiogenesis (the formation of new blood vessels by tumours).[18]
It was also proposed that it might act by inducing autophagy, as some other tyrosine kinase inhibitors, like sorafenib.[19]
It has also been shown[16] to bind (in a different conformation from the VEGF binding) to the BCR-ABL fusion protein, specifically inhibiting the drug-resistant T315I mutant isoform.
| Protein | IC50 (nM) |
|---|---|
| VEGFR1 | 0.1 |
| VEGFR2 | 0.2 |
| VEGFR3 | 0.1-0.3 |
| PDGFR | 1.6 |
| c-KIT | 1.7 |
Pharmacokinetics
| Bioavailability | Tmax | Cmax | AUC | Vd | Plasma protein binding | Metabolising enzymes | t1/2 | Excretion routes |
|---|---|---|---|---|---|---|---|---|
| 58% | 2.5-4.1 hr | 27.8 ng/mL | 265 ng•h/mL | 160 L | >99% | Mostly CYP3A4 and CYP3A5. Lesser contributions from CYP1A2, CYP2C19, UGT1A1 | 2.5-6.1 hr | Faeces (41%), urine (23%) |
Society and culture
Brand names
In Bangladesh it is under the trade name Axinix.[citation needed]
In Germany , Switzerland and other European countries it is available under the trade name Inlyta.[20][21]
References
- ↑ 1.0 1.1 "Inlyta- axitinib tablet, film coated". DailyMed. Pfizer Inc.. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=84137882-e000-47da-bd5b-fa76ab3c76f9.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 "Inlyta (axitinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. http://reference.medscape.com/drug/inlyta-axitinib-999715#showall.
- ↑ "AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging". Magnetic Resonance Imaging 25 (3): 319–327. April 2007. doi:10.1016/j.mri.2006.09.041. PMID 17371720.
- ↑ "AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC)". Journal of Clinical Oncology ASCO Annual Meeting Proceedings 23 (16S): 4509. June 2005. http://meeting.ascopubs.org/cgi/content/abstract/23/16_suppl/4509.
- ↑ "Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results". Journal of Clinical Oncology 23 (24): 5474–5483. August 2005. doi:10.1200/JCO.2005.04.192. PMID 16027439.
- ↑ "FDA Approves Inlyta for Advanced Renal Cell Carcinoma". January 27, 2012. https://www.drugs.com/newdrugs/fda-approves-inlyta-advanced-renal-cell-carcinoma-3072.html.
- ↑ "The Slippery Slope: Is a Surrogate Endpoint Evidence of Efficacy?". MedPage Today. October 27, 2014. http://www.medpagetoday.com/PublicHealthPolicy/FDAGeneral/48244.
- ↑ "Inlyta : EPAR - Product Information". European Medicines Agency. Pfizer Ltd.. 17 December 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002406/WC500132188.pdf.
- ↑ "Inlyta 1 mg 3mg, 5 mg & 7mg film-coated tablets - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Pfizer Limited. 5 December 2013. http://www.medicines.org.uk/emc/medicine/27051/SPC/Inlyta+1+mg+3mg%2c+5+mg+%26+7mg+film-coated+tablets/.
- ↑ "PRODUCT INFORMATION INLYTA (axitinib)" (PDF). TGA eBusiness Services. Pfizer Australia Pty Ltd.. 5 July 2013. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2012-PI-02467-1.
- ↑ "Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study". Lancet 371 (9630): 2101–2108. June 2008. doi:10.1016/S0140-6736(08)60661-3. PMID 18514303.
- ↑ "Pfizer pancreatic cancer drug fails, trial halted". Reuters. January 30, 2009. https://www.reuters.com/article/marketsNews/idINN3039502020090130?rpc=44.
- ↑ "Pfizer's Phase III Trial in mRCC Turns Up Positive Results". 19 Nov 2010. http://www.genengnews.com/gen-news-highlights/pfizer-s-phase-iii-trial-in-mrcc-turns-up-positive-results/81244271/.
- ↑ "ODAC Unanimously Supports Axitinib for Renal Cell Carcinoma". 7 Dec 2011. http://www.onclive.com/web-exclusives/ODAC-Unanimously-Supports-Axitinib-for-Renal-Cell-Carcinoma.
- ↑ "ALK1/VEGF Combo Active in Advanced RCC. Jan 2017". http://www.cancernetwork.com/renal-cell-carcinoma/alk1-vegf-combo-active-advanced-rcc.
- ↑ 16.0 16.1 "Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation". Nature 519 (7541): 102–105. March 2015. doi:10.1038/nature14119. PMID 25686603. Bibcode: 2015Natur.519..102P.
- ↑ "FDA Prescribing Information". 30 Jan 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202324lbl.pdf.
- ↑ "Axitinib for the management of metastatic renal cell carcinoma". Drugs in R&D 11 (2): 113–126. 2011. doi:10.2165/11591240-000000000-00000. PMID 21679004.
- ↑ "Screening of kinase inhibitors targeting BRAF for regulating autophagy based on kinase pathways". Molecular Medicine Reports 9 (1): 83–90. January 2014. doi:10.3892/mmr.2013.1781. PMID 24213221.
- ↑ AHFS Patient Medication Information [Internet]. Bethesda (MD): American Society of Health-System Pharmacists, Inc.; c2022. Axitinib; [last revised 2020 August 15; cited 2022 March 28]; [about 5 p.]. Available from: https://medlineplus.gov/druginfo/meds/a612017.html
- ↑ "Axitinib" (in en). PubChem. U.S. National Library of Medicine. https://pubchem.ncbi.nlm.nih.gov/compound/6450551.
External links
- "Axitinib". Drug Information Portal. U.S. National Library of Medicine. https://druginfo.nlm.nih.gov/drugportal/name/axitinib.
 |  |
